Engineering Specific Human iPS Reporter Cell Lines to Generate Optogenetically Modified Photoreceptors

Area of Science:

• Ophthalmology
• Neuroscience
• Biotechnology

Background:

• Photoreceptor degenerative diseases cause vision loss.
• Current cell therapy for these diseases requires transplanted cells to mature fully, forming outer segments and integrating with retinal pigmented epithelium (RPE).
• This maturation process is a significant hurdle for successful cell transplantation.

Purpose of the Study:

• To develop a novel cell therapy approach for photoreceptor degenerative diseases.
• To overcome the limitations of traditional cell therapy by conferring light sensitivity to transplanted cells.
• To create genetically engineered induced pluripotent stem cells (iPSCs) for optogenetic vision restoration.

Main Methods:

• Utilized CRISPR/Cas9 gene editing at the AAVS1 locus to insert the Jaws microbial opsin gene into the iPSC genome.
• Engineered iPSCs to express Jaws, a red-light sensitive chloride pump, under a specific photoreceptor promoter.
• Generated and validated a knock-in Jaws-EGFP iPSC line, confirming its stemness and pluripotency.

Main Results:

• Successfully generated a stable iPSC line engineered to express the Jaws-EGFP fusion protein.
• Validated the pluripotency and stemness of the engineered iPSCs.
• The engineered cells are prepared for differentiation into photoreceptors for transplantation.

Conclusions:

• Optogenetic modification of iPSC-derived photoreceptors offers a promising strategy for treating blindness.
• This approach bypasses the need for mature outer segment formation and RPE contact for light sensitivity.
• Further studies will assess the efficacy of these engineered cells in restoring vision in animal models.